There were 30 press releases posted in the last 24 hours and 166,535 in the last 365 days.

Biosimilar Market to Reach $15.6 billion with 23.8% CAGR Forecast to 2022

Biosimilar Market to Grow at a 23.8% CAGR Forecast to 2022

PUNE, INDIA, October 12, 2016 /EINPresswire.com/ -- According to researcher, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs has experienced robust market growth. Some of the factors which are triggering the market growth include growing incidences of diseases, rising demand for biosimilars drugs owing to their cost effectiveness and increasing demand to limit healthcare expenditures. However, stringent government regulations will affect biosimilars investments.

Request a sample report @ https://www.wiseguyreports.com/sample-request/674240-biosimilar-global-market-outlook-2016-2022

Chronic & Autoimmune disorders segment is expected to grow at a highest CAGR during the forecast period owing to increasing incidences of autoimmune disorders. By geography, Europe dominated the global biosimilars market due to growing appearance of new market participants in this region. However, Asia Pacific is anticipated to grow at a highest CAGR during the forecast period due to rising funds towards the expansion of biosimilars market.

Some of the key players in this market include are Mylan, Inc., Dr. Reddy's Laboratories, Amgen Inc., Sandoz International GmbH , Hospira, Inc., Merck KGAA, Celltrion, Inc., Biocon Ltd. , Teva Pharmaceutical Industries Ltd. and Roche Diagnostics.

Products Covered:
• Peptides
• Erythropoietin
• Interferon
• Human Growth Hormone
• Monoclonal Antibodies
• Granulocyte Colony Stimulating Factor (G-CSF)
• Insulin
• Other Products
Technology Covered:
• Bioassay
• Mass Spectrometry
• Nuclear magnetic resonance (NMR) technology
• Recombinant DNA Technology (rDNA technology)
• Western Blotting
• Electrophoresis
• Chromatography
• Monoclonal Antibodies (MAb) Technology
Application Covered:
• Growth Hormone Deficiency
• Chronic and Autoimmune Diseases
• Blood Disorders
• Oncology Diseases
• Other Applications
Service Covered:
• Clinical Trials
• Contract Research and Manufacturing Services

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=674240

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Key points in table of content
1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 Emerging Markets

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Biosimilar Market, By Product
5.1 Introduction
5.2 Peptides
5.3 Erythropoietin
5.4 Interferon
5.5 Human Growth Hormone
5.6 Monoclonal Antibodies
5.7 Granulocyte Colony Stimulating Factor (G-CSF)
5.8 Insulin
5.9 Other Products

6 Global Biosimilar Market, By Technology
6.1 Introduction
6.2 Bioassay
6.3 Mass Spectrometry
6.4 Nuclear magnetic resonance (NMR) technology
6.5 Recombinant DNA Technology (rDNA technology)
6.6 Western Blotting
6.7 Electrophoresis
6.8 Chromatography
6.8.1 Gas Chromatography (GC)
6.8.2 Protein sequencing
6.8.3 Liquid chromatography (LC)
6.9 Monoclonal Antibodies (MAb) Technology

7 Global Biosimilar Market, By Application
7.1 Introduction
7.2 Growth Hormone Deficiency
7.3 Chronic and Autoimmune Diseases
7.3.1 Leprosy
7.3.2 Rheumatoid arthritis (RA)
7.3.3 Multiple Sclerosis
7.3.4 Diabetes
7.3.5 Acromegaly
7.3.6 Cystic Fibrosis
7.3.7 Neutropenia
7.4 Blood Disorders
7.4.1 Pulmonary embolism
7.4.2 Hemophilia
7.5 Oncology Diseases
7.5.1 Leukaemia
7.5.2 Colorectal Cancer
7.5.3 Breast Cancer
7.5.4 Prostate Cancer
7.5.5 Cervical Cancer
7.5.6 Lungs Cancer
7.6 Other Applications

8 Global Biosimilar Market, By Service
8.1 Introduction
8.2 Clinical Trials
8.2.1 Phase I
8.2.2 Phase II
8.2.3 Phase III
8.3 Contract Research and Manufacturing Services

9 Global Biosimilar Market, By Geography
9.1 North America
9.1.1 US
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 UK
9.2.5 Spain
9.2.6 Rest of Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 Australia
9.3.5 New Zealand
9.3.6 Rest of Asia Pacific
9.4 Rest of the World
9.4.1 Middle East
9.4.2 Brazil
9.4.3 Argentina
9.4.4 South Africa
9.4.5 Egypt

10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling
11.1 Mylan, Inc.
11.2 Dr. Reddy's Laboratories
11.3 Amgen Inc.
11.4 Sandoz International GmbH
11.5 Hospira, Inc.
11.6 Merck KGAA
11.7 Celltrion, Inc.
11.8 Biocon Ltd.
11.9 Teva Pharmaceutical Industries Ltd.
11.10 Roche Diagnostics
11.11 Biogen idec Inc.
11.12 LG Life Sciences
11.13 Synthon Pharmaceuticals, Inc.
11.14 Novartis AG

Complete report details @ https://www.wiseguyreports.com/reports/674240-biosimilar-global-market-outlook-2016-2022

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here